Cat. No. | Product name | CAS No. |
DC66955 | CDX-1401 Featured | |
DC66956 |
Ontamalimab
Featured
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease. |
2098790-40-8 |
DC66957 | CT Atlantic patent anti-MAGE-A3 Featured | |
DC66958 | IMC-C103C Featured | |
DC66959 |
Narsoplimab
Featured
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2. |
2108782-45-0 |
DC66960 | Oxford Bio patent anti-Matriptase Featured | |
DC66961 | Tokai U. Patent Anti-Meflin Featured | |
DC66962 | SC-005 Featured | |
DC66963 | RGX-019 Featured | |
DC66964 |
Amatuximab
Featured
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium. |
931402-35-6 |
DC66965 | BMS-986148 Featured | |
DC66966 |
Anetumab
Featured
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor. |
1954758-84-9 |
DC66967 | NIH patent anti-Mesothelin Featured | |
DC66968 | CLN-619 Featured | |
DC66969 | U.Washington patent anti-MICB Featured | |
DC66970 |
Imalumab
Featured
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer. |
1430205-07-4 |
DC66971 |
Andecaliximab
Featured
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF). |
1518996-49-0 |
DC66972 | Yeda patent anti-MMP-9 Featured | |
DC66973 | Anti-MPL/TPOR/CD110 Antibody (TA136) Featured | |
DC66974 | Copenhagen Rigshospitalet patent anti-uPARAP Featured | |
DC66975 | Quark patent anti-ENDO 180 Featured | |
DC66976 |
Narnatumab
Featured
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer. |
1188275-92-4 |